Skip to main content

Table 3 Changes in CT-1 and hs-CRP levels of eligible patients before and after treatment

From: Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial

  Baicalin (n = 166) Placebo (n = 165)
Baseline Post treatment Baseline Post treatment
CT-1 194.6 ± 42.3 42.9 ± 13.7 * 187.4 ± 39.1 128.4 ± 24.3 *#
hs-CRP 32.4 ± 2.3 1.64 ± 0.38 * 30.8 ± 2.7 3.9 ± 1.4 *#
  1. Values are mean ± SD. *p < 0.05 compared to baseline within the same group; #p < 0.05 compared at the same time point between two groups. CT-1 cardiotrophin-1, hs-CRP high-sensitivity C-reactive protein